Results Provide Hope
INDIANAPOLIS, IN-Eli Lilly has stopped enrollment in a Phase III clinical trial investigating the therapeutic potential of recombinant, human-activated protein C in the treatment of severe sepsis. The decision was based upon the recommendation of an independent Data and Safety Monitoring Board (DSMB) that was conducting a regularly scheduled interim analysis. The DSMB found positive trial results that met the pre-determined criteria for reduced mortality.
According to August M. Watanabe, MD, executive vice president, science and technology for Lilly, no pharmacological agents are currently approved to treat sepsis, a disease characterized by an overwhelming systemic response to infection, which can rapidly lead to organ failure and death. Sepsis has a 30 to 50% mortality rate and often occurs in hospitalized patients. It is the leading cause of death in non-coronary intensive care units in the US.
Researchers have found that sepsis patients have a very low amount of protein C. When protein C levels are low, the body cannot convert much of it to the activated form, APC. Hence, coagulation and inflammation are "unchecked," resulting in serious complications. Lilly researchers believe their manufactured protein will prevent clot formation, break up clots already in existence, and reduce the inflammation that occurs in blood vessels.
If results of the full evaluation support an application and consequent receipt of approval from the Food and Drug Administration, Lilly management will market the protein as Zovant(TM).
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.